Lansoprazole - Apricus Biosciences

Drug Profile

Lansoprazole - Apricus Biosciences

Alternative Names: PrevOnco

Latest Information Update: 12 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator FasTrack Pharmaceuticals
  • Developer Apricus Biosciences
  • Class Antiulcers; Benzimidazoles; Gastric antisecretories; Pyridines; Small molecules; Sulfoxides
  • Mechanism of Action Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Liver cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Liver cancer

Most Recent Events

  • 08 Mar 2016 Biomarkers information updated
  • 27 Aug 2015 No recent reports on development identified - Phase-II for Liver cancer (First-line therapy) in USA (PO)
  • 19 Apr 2012 Lansoprazole - Apricus Biosciences is available for licensing as of 13 Mar 2012. http://www.apricusbio.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top